Vir Biotech Q3 revenue $374.6M; BARDA contract up to $1B; Phase 2 data in 2023

Vir Biotechnology, Inc.

2022-Q3 EPS reported $4.58 revenue$1,566,387,000

Q3 2022 revenue $374.6M (vs $103.6M YoY); net income $175.3M ($1.32 basic EPS) vs $110.4M ($0.85) in Q3 2021.
BARDA awards contract for pandemic preparedness: initial ~$55M, potential up to $1B.
GSK opted-in to collaborate on RSV antibodies; profit-sharing from GSK $291.2M in Q3.
Phase 2 trials for HBV, HDV (SOLSTICE), influenza A (PENINSULA); initial data expected in 2023.
Strong balance sheet: ~$2.7B cash, investments, and profit-share payments.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vir Biotechnology, Inc. reported financial results for third quarter ended September 30, 2022.

Period: third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 3, 2022, Vir Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Vir Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-021846

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.